Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Remsima Infliximab Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis Withdrawn
Renflexis infliximab rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis Reimburse with clinical criteria and/or conditions Complete
Repatha Evolocumab Primary hyperlipidemia and mixed dyslipidemia Reimburse with clinical criteria and/or conditions Complete
Repatha Evolocumab Primary hyperlipidemia; mixed dyslipidemia List with clinical criteria and/or conditions Complete
Repatha evolocumab Primary hyperlipidemia Reimburse with clinical criteria and/or conditions Active
Replagal Agalsidase alfa Fabry Disease Do not list Complete
Resotran Prucalopride Constipation, chronic Do not list Complete
Restasis ophthalmic emulsion Cyclosporine Dry eye disease Do not list Complete
Retevmo selpercatinib RET fusion-positive non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Retevmo selpercatinib Thyroid cancer Reimburse with clinical criteria and/or conditions Complete